Preclinical Study Services for Cardiovascular Drugs

Preclinical evaluation of cardiovascular drugs plays an irreplaceable role in predicting potential drug toxicity prior to their first application to humans. Ace Therapeutics provides in vitro and in vivo preclinical studies of cardiovascular drugs to provide a theoretical basis for subsequent trials and clinical risk.

Overview of Drug Preclinical Research for Cardiovascular Drugs

In the development of new drugs for cardiovascular diseases, once a drug candidate has been identified, the next step is to conduct preclinical safety, pharmacokinetic, pharmacodynamic, and pharmacologically relevant studies to observe the biological activity of the compound in specific cardiovascular diseases and to assess the safety of the compound to support the initiation of clinical trials.

• Pharmacokinetics/Pharmacodynamics (PK/PD)
  Understanding the absorption, distribution, metabolism, and excretion (ADME) of drugs in animals, these data can guide clinical studies to determine the form of administration as well as the frequency and dose of administration.
• Safety Pharmacology
  In addition to demonstrating that the compound is biologically active against a specific target disease, there is a need to assess the effects of the drug beyond efficacy, such as possible side effects, especially on the cardiovascular, respiratory, and central nervous systems.
• Toxicology
  Drug toxicity studies including acute toxicity, chronic toxicity, reproductive toxicity, carcinogenicity, and mutagenicity need to be completed before a new drug can enter clinical studies.

Fig. 1 Overview of phase I and phase II drug-metabolism. (Smolders EJ, et al., 2019)

Ace Therapeutics offers in vitro and in vivo preclinical study services for cardiovascular drugs, including preclinical pharmacodynamic studies, safety pharmacology studies, toxicology studies, and pharmacokinetic studies, which provide reference data and theoretical bases for subsequent clinical trials and clinical risks.

Ace Therapeutics specializes in drug discovery and development for cardiovascular disease. With professional equipment platforms and dedicated research teams, we can provide preclinical research services for cardiovascular drugs according to the customized needs of our clients. If you are interested in our services, please don't hesitate to contact us.

1. Smolders, E.J.; et al. Cardiovascular risk management and hepatitis C: Combining Drugs. Clin Pharmacokinet. 2019, 58(5): 565-592.